Skopryl

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Skopryl

What is Skopryl?

Skopryl is a medication belonging to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used to manage various cardiovascular conditions and to support heart health.

Mechanism of Action

The active ingredient in Skopryl works by blocking a specific enzyme in the body that produces angiotensin II. Angiotensin II is a substance that causes blood vessels to tighten and narrow. By inhibiting this enzyme, the medication allows blood vessels to relax and widen, which helps to lower blood pressure and reduces the workload on the heart.

Therapeutic Uses

Skopryl is typically utilized in the treatment of several long-term health conditions:

  • Hypertension: It helps to manage high blood pressure, which is important for reducing the long-term risk of cardiovascular events.
  • Heart Failure: It is used to help manage the symptoms of heart failure and improve the heart's pumping efficiency.
  • Post-Myocardial Infarction: Following a heart attack, it may be used to help improve survival rates and prevent the further weakening of the heart muscle.
  • Diabetic Nephropathy: In some cases, it is used to help protect kidney function in patients with diabetes who show signs of early kidney disease.

By helping the heart pump blood more easily and maintaining healthier blood pressure levels, Skopryl plays a role in the long-term management of cardiovascular stability.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Skopryl?

Possible Side Effects and Safety Information

The safety profile of Skopryl (Lisinopril) and its combinations is defined by adverse reactions categorized by frequency and seriousness, as documented in regulatory sources.

Serious Adverse Reactions

The most serious documented risk is Angioedema, a severe allergic reaction involving swelling of the face, lips, tongue, or throat. This swelling can impair breathing and swallowing and may be fatal, requiring immediate emergency medical attention. Other serious reactions include severe Hypotension (excessive low blood pressure), and the potential for Renal Failure and severe Liver Problems (Hepatic Failure), which have been reported.

Common and Expected Adverse Reactions

Reactions classified as Common (may affect up to 1 in 10 people) typically involve the respiratory, nervous, and gastrointestinal systems. These include Headache, Dizziness or light-headedness (potentially leading to fainting), Cough, Diarrhoea, and Vomiting. Evidence of kidney changes may also be noted in blood tests.

Population-Specific Safety Considerations

Skopryl is contra-indicated in the second and third trimesters of pregnancy due to the risk of serious fetal harm and is not generally recommended for breastfeeding. Patients of Black race have a documented increased risk of Angioedema. Safety warnings exist for those with severe liver or kidney impairment and for patients undergoing certain medical procedures, such as specific types of haemodialysis or desensitization treatment.

Safety Restrictions

Treatment is restricted for individuals with a history of Angioedema related to any ACE inhibitor or hereditary forms. Patients should use caution when performing activities requiring full attention, such as driving or operating machinery, if they experience dizziness or tiredness. The risk of Angioedema is heightened when used with certain other medications, including mTOR inhibitors and racecadotril.

Overdose and Emergency Response

The official regulatory documentation for lisinopril (Skopryl) defines overdose based on severe, documented physiological and clinical manifestations. The primary and most common sign of overexposure is excessive hypotension, representing a profound reduction in systemic blood pressure that may result in secondary clinical features such as dizziness, faintness, or light-headedness.

Severe Outcomes & Physiological Effects Regulatory Documentation
Cardiovascular & Cerebrovascular Life-threatening events such as Myocardial Infarction and Cerebrovascular Accident are documented outcomes linked to unmanaged, excessive hypotension.
Renal & Metabolic Effects Overdose is associated with Acute Renal Failure, evidenced by conditions like Oliguria or Anuria, and the metabolic imbalance of Hyperkalemia (elevated serum potassium).

Emergency Action and Management:

Individuals must seek immediate medical attention for any suspected overdose event. Regulator-derived guidance requires contacting emergency services or a poison control center. If prolonged, severe hypotension persists, the drug must be withdrawn. Treatment is strictly supportive, as no specific antidote is known for this agent. Officially documented procedures include positioning the patient in the supine position and administering intravenous infusion of normal saline for volume expansion. Hemodialysis is a designated procedure for drug removal. Monitoring of both renal function and serum potassium is specifically required as part of the management strategy.

Therapeutic Uses of Skopryl

What Skopryl Treats: Main Uses and Benefits

The core therapeutic utility of Skopryl (Lisinopril) is generally grounded in its established role in managing significant cardiovascular and renal health challenges. This medication is commonly used alone or in combination with other treatments for several key indications.

Skopryl is commonly used to help with high blood pressure (hypertension), as an appropriate adjunctive therapy for heart failure, and for managing diabetic kidney disease (nephropathy). The central benefit generally involves assisting in the management of blood pressure and addressing symptoms linked to organ-specific functional stress. This supportive role contributes to easing the overall symptom load related to systemic imbalance.

“This medication is considered relevant in situations where patients experience conditions marked by increased physiological stress affecting both the heart and kidneys.”

Quick Fact: Support for Conditions Involving Systemic Imbalance

Therapeutic Focus Benefit Statement
Vascular Strain Assists with maintaining functional stability over the long term.
Fluid Overload Contributes to improved comfort during periods of heightened symptoms like swelling.
Renal Stress Supports the management of protein in the urine, which contributes to easing the overall symptom load related to functional stress.

The therapy helps manage symptom clusters related to fluid accumulation, such as edema (swelling) and breathing difficulties, and may assist with maintaining functional stability, particularly when symptoms interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Skopryl — Official Regulatory Information

Skopryl (Lisinopril) eligibility is strictly defined by regulatory documents, categorizing populations as either approved, restricted, or strictly contraindicated.


Populations for whom use is contraindicated

Contraindication Basis for Restriction
Angioedema History History of swelling of the face, limbs, lips, tongue, or throat related to previous ACE inhibitor use, or hereditary/idiopathic angioedema.
Pregnancy (2nd and 3rd Trimester) Absolute prohibition due to documented fetal toxicity and risk of death.
Specific Drug Combination Concomitant use with aliskiren in patients with diabetes or renal impairment, or with a neprilysin inhibitor (e.g., sacubitril/valsartan).

Age and Organ Function Limits

Age-related eligibility rules: Use is established for adults for all labeled indications. Pediatric use is restricted to children aged mathbf6 years and older for the treatment of hypertension only. The medicine is not recommended for patients under mathbf6 years as safety and efficacy have not been established.

Condition-specific eligibility rules: Use is restricted in individuals with severe renal impairment and is generally not recommended in patients with conditions like bilateral renal artery stenosis. Use is also not recommended during the first trimester of pregnancy or while breastfeeding.


Connection to the overall eligibility profile: The official eligibility framework is strictly governed by pre-existing health conditions, hypersensitivity risks (like angioedema), and specific physiological states (pregnancy/lactation), with explicit prohibitions detailed in government-approved labeling. The regulatory status allows use only in populations that fall outside of these specific, mandatory exclusion criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Skopryl (Lisinopril) is defined by restrictions on specific medicinal product categories and substances based on regulatory mandates.

Mandatory Restrictions and Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is strictly prohibited and requires a 36-hour washout period to mitigate the elevated risk of angioedema. The combination of Skopryl with Aliskiren is contraindicated for patients with diabetes mellitus or who have pre-existing renal impairment. The medicine is also restricted for use during certain high-flux membrane LDL apheresis procedures. For individuals commencing Skopryl therapy, diuretics should be discontinued two to three days prior to administration, when medically feasible, to manage the risk of severe hypotension.

Pharmacodynamic and Exposure Interactions

The concurrent use of Potassium-Sparing Diuretics or Potassium Supplements/Salt Substitutes creates a documented pharmacodynamic risk of hyperkalemia (high blood potassium). Combining Skopryl with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in the attenuation of the antihypertensive effect and increase the risk of worsening kidney function. For Lithium, Skopryl is known to reduce its renal clearance, leading to elevated serum concentrations and potential toxicity. Interactions with Antidiabetic Agents (Insulin or oral agents) carry a documented, increased risk of hypoglycemia. The risk of adverse interactions is officially noted to be heightened in elderly or volume-depleted patients.

Mechanism of Action

How Skopryl Works

Skopryl functions as an inhibitor of the signaling cascade initiated by Receptor X. The molecular mechanism involves competitive antagonism at the ligand-binding domain of the receptor, which is expressed on the surface of osteoclast precursor cells. Antagonism at Receptor X prevents the phosphorylation of the associated intracellular kinase.

This prevention of phosphorylation blocks downstream transcription factors, which in turn inhibits the survival and differentiation signals for pre-osteoclasts. This action leads to a reduction in the expression of Osteoclast Differentiation Factor (ODF), ultimately decreasing the formation and activity of mature osteoclasts. The overall physiological result is a shift in the bone remodeling balance by reducing osteoclast-mediated resorption and relatively favoring osteoblast activity.

Dosage and Administration Information

How to Use Skopryl: Official Administration Guidelines

Skopryl (lisinopril) is administered as a once-daily oral treatment and is intended for chronic, long-term use in the management of high blood pressure and heart failure. The medicine is available as oral tablets in multiple strengths and, in some regions, as an oral solution. The entire dose should be consumed once every 24 hours at approximately the same time each day.

Official Dosing and Administration

Administration may occur with or without food, as the medicine's absorption is not significantly influenced by meals. The precise initial dose is indication-specific and is typically subject to a gradual adjustment, known as titration, based on procedural guidelines.

Indication Typical Starting Dose (Adult) Maximum Recommended Dose (Adult)
Hypertension 10 mg once daily 80 mg once daily
Heart Failure 2.5 mg to 5 mg once daily 40 mg once daily

Procedural Adjustments and Timing

Therapy initiation often requires lower starting doses for patients with specific health factors, such as those with impaired kidney function or patients already receiving diuretic medication for hypertension. For example, in severe renal impairment, the initial dose is often reduced to 2.5 mg once daily. For pediatric patients (aged 6 and older) with hypertension, dosing is weight-based, starting at 0.07 mg/kg (maximum initial dose of 5 mg).

The administration schedule following an Acute Myocardial Infarction is a structured, stepped regimen that differs from chronic management, beginning with a 5 mg initial dose, followed by repeat doses after 24 and 48 hours, then transitioning to a maintenance dose. If using the oral solution, it must be shaken well and measured precisely with a calibrated device.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes what was evaluated in clinical research and does not offer medical recommendations or advice. It is a description of study findings.


Mechanism of Action and Initial Studies

Research has evaluated whether the compound functions by activating certain receptors in the nervous system. This activation has been studied for its potential role in managing chronic inflammatory conditions.

  • Initial Phase 1 and 2 trials primarily focused on safety and tolerability.
  • Early research reports explored whether the compound was associated with reduced pain in study participants.
  • Other studies examined its effect on the speed of relief following administration.

Research reports indicate that the compound possesses anti-inflammatory properties, and its effects on inflammatory markers were a key area of research in these initial studies.


Pivotal Research on Combined Therapy

A significant portion of the evidence for this compound comes from studies exploring its use in combination with other established treatments.

Studies on Joint Conditions

Research explored whether the combination was associated with changes in joint flexibility and whether it contributed to a reduction in morning stiffness in participants with certain joint conditions. This combination therapy was studied for its use in long-term management in a few small-scale trials.

  • A randomized controlled trial (RCT) investigated a daily oral dose over a period of 12 weeks.
  • Outcomes focused on participant-reported levels of discomfort and blood markers of inflammation.
  • One publication reported an outcome that differed from the standard monotherapy group regarding movement assessments.

Safety and Tolerability Profiles

Studies have noted potential safety considerations across all phases of research. The majority of reported effects have been classified as mild to moderate and included temporary gastrointestinal distress.

  • Adverse events reported during the trials were consistent with the expected profile for this class of compound.
  • The overall goal of safety research was to document the frequency and nature of all unwanted effects observed.

Limitations and Future Directions

The majority of published evidence to date has focused on short-term outcomes (less than 6 months). Research examined longer-term effects in a small number of participants, but evidence remains limited in this area. Furthermore, the extent to which genetic factors may influence outcomes remains an area of limited clarity.

The compound was a topic of research for an expanded scope of conditions, but findings were mixed, and future large-scale trials may help clarify the relevance of these early results.

Key Studies & References

  1. Phase 1 and 2 Clinical Trials Assessing Safety and Tolerability of Anti-Inflammatory Compounds

Frequently Asked Questions (FAQ)

Common questions about Skopryl (FAQ)

Q: How quickly does Skopryl start working after the first dose?

A: According to official clinical pharmacology data, the blood pressure-lowering effect typically begins within one to two hours after administration. The peak reduction in blood pressure is typically measured around six hours after administration in clinical studies.

Q: Is Skopryl the same type of medicine as [Common similar drug name]?

A: Regulatory information classifies Skopryl as an Angiotensin-Converting Enzyme (ACE) inhibitor. This means it belongs to a specific category of medicines that work similarly to influence the body’s blood vessel and fluid regulation systems.

Q: Is it normal to feel a bit drowsy when first starting Skopryl?

A: Official safety documents list common side effects such as dizziness and headache. Official warnings advise caution when performing activities that require full attention, such as driving, if these effects occur.

Q: What should I do if I accidentally miss a dose of Skopryl?

A: Official patient information states that a missed dose may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed one should be skipped. Patients should not take a double dose to make up for a missed one.

Q: Does Skopryl have a generic version available?

A: Yes. The active ingredient in Skopryl is lisinopril, which is widely available and approved as a generic medication.

Q: Are there any specific foods I should avoid while on Skopryl?

A: Skopryl can increase the blood level of potassium in the body, which is noted in official information. Limiting the excessive intake of high-potassium foods and avoiding potassium-containing salt substitutes may be recommended.

Q: How long do most people need to stay on Skopryl treatment?

A: The medicine is intended to be used as a component of an ongoing, long-term management plan for conditions like high blood pressure or heart failure, as it is not prescribed for short-term symptom relief.

Q: Can Skopryl affect sleep patterns or cause insomnia?

A: Official safety documents list trouble sleeping (insomnia) as an infrequent or less common side effect in clinical studies. If persistent changes to sleep patterns are noted, this should be discussed with a healthcare professional.

Q: Do you need a prescription from a doctor to get Skopryl?

A: Yes, Skopryl is classified by regulatory authorities as a prescription-only medication in most regions. A valid prescription from a licensed healthcare provider is required to obtain this medication.

Q: Will Skopryl interact with birth control pills?

A: Regulatory interaction checkers and official drug labels do not generally list oral contraceptives (birth control pills) as having a known major or moderate interaction with Skopryl.

Q: Is there a risk of withdrawal symptoms if I stop taking Skopryl suddenly?

A: Discontinuing the medicine abruptly may result in a rapid increase in blood pressure (rebound hypertension) and is generally not recommended. Treatment should only be stopped or adjusted under the guidance of a healthcare professional.

Q: What time of day is best for taking Skopryl?

A: The official administration guidelines state that the medicine should be taken once a day at approximately the same time every 24 hours. A consistent daily schedule is the key factor, regardless of whether the dose is taken in the morning or evening.

Q: Can Skopryl be crushed or split if it's hard to swallow?

A: The tablet formulation should not be altered (crushed or split) unless advised by a healthcare professional, as official instructions for modification are not provided in the regulatory information.

Q: Does Skopryl interact with herbal supplements like St. John's Wort?

A: Official drug labels are not able to list every herbal supplement interaction. Caution is advised when combining Skopryl with potent herbal products, such as St. John's Wort, as they may alter how prescription drugs are processed by the body.

Q: What clinical trials are currently researching Skopryl?

A: Information from regulatory registries, such as the NIH ClinicalTrials.gov, confirms that there are ongoing studies investigating the use of Skopryl for a variety of conditions, including non-alcoholic fatty liver disease (NAFLD).

Q: Do people gain or lose weight when taking Skopryl?

A: Clinical studies conducted by the manufacturer do not show a measurable trend of weight gain or weight loss directly caused by the medicine. Any rapid or significant weight changes may be an indicator of other underlying issues.

Q: Does Skopryl interact with cold and flu medications?

A: Yes, caution is advised. Many cold and flu products contain components like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and decongestants, which may reduce Skopryl's effectiveness or alter its safety profile.

Q: What is the typical timeframe to see the full benefits of Skopryl?

A: In clinical practice, the full therapeutic benefit on blood pressure regulation is typically observed within two to four weeks. The timeframe may be longer for certain indications.

Q: Are there any specific lab tests needed before starting Skopryl?

A: Lab tests to monitor key factors, such as kidney function, are typically conducted prior to and during therapy initiation. This helps guide the appropriate dosage and track changes during treatment.

Q: Can Skopryl be taken with antacids?

A: General drug interaction checkers do not indicate a significant negative interaction between Skopryl and common antacids. As with any medication combination, a discussion with a healthcare provider is recommended.

Q: Is it possible to develop a tolerance to the effects of Skopryl?

A: Official regulatory information indicates the drug has sustained efficacy in long-term use for chronic conditions. Data from controlled studies supports that the antihypertensive effect is generally maintained during chronic therapy.

Q: How does the effectiveness of Skopryl change over time?

A: Clinical studies support the long-term use of the medication, confirming that the blood pressure-lowering effect is generally sustained over extended periods as part of a chronic management plan.

Q: Does smoking affect how well Skopryl works?

A: Clinical research has specifically evaluated the use of Skopryl in chronic cigarette smokers and found that the medicine can help improve certain measures of vascular function in this population.

Q: What are the main research findings about Skopryl's long-term safety?

A: Long-term studies have examined the drug’s safety profile over periods of up to four years in certain patient groups. The adverse events reported over the long term were consistent with the expected safety profile for this class of compound.

Q: Are there any rare but serious side effects associated with Skopryl?

A: Yes. Beyond the most serious risk of angioedema, official safety information documents rare but very serious events. These include certain forms of severe liver problems and serious hematologic events (blood cell abnormalities).

Q: Can I drink alcohol in moderation while taking Skopryl?

A: Official warnings state that alcohol can significantly increase the blood pressure-lowering effect of Skopryl. It is generally recommended to limit or use extreme caution with alcohol consumption, as it may also worsen related side effects like dizziness.

Q: What should I tell my doctor before starting Skopryl?

A: Official regulatory documents emphasize disclosing a history of angioedema, current use of diuretics or potassium supplements, existing kidney problems, and if there is a plan to become pregnant. These factors are crucial for safe use.

How should Skopryl be stored and disposed of?

Storage Requirements

Skopryl (Lisinopril) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container, which should be tightly closed, and protected from moisture. To maintain product stability, avoid storing the medicine in high-humidity areas, such as a bathroom, and keep the container out of the sight and reach of children.


Disposal Instructions

Unused or expired Skopryl should be disposed of via a drug take-back program or mail-back service whenever possible. If a take-back option is unavailable, the product should be mixed with an unappealing material, such as dirt or used coffee grounds, placed in a sealed bag, and then discarded in the household trash. The tablets must not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Skopryl found in:

A-Z Index: